Effects of topical low-dose preservative-free hydrocortisone on intraocular pressure in patients affected by ocular surface disease with and without glaucoma.
Intraocular pressure
Ocular surface disease
Open-angle glaucoma
Topical hydrocortisone
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
28
12
2020
accepted:
26
07
2021
revised:
05
07
2021
pubmed:
19
8
2021
medline:
20
1
2022
entrez:
18
8
2021
Statut:
ppublish
Résumé
This study aims to investigate the safety and efficacy of short-term treatment for ocular surface disease (OSD) with topical low-dose (1,005 mg) preservative-free hydrocortisone in one hundred patients with and without glaucoma. This was an open label non-randomized clinical trial. Patients with OSD with and without primary open-angle glaucoma (POAG) received topical low-dose (1,005 mg) preservative-free hydrocortisone twice daily in each eye for 2 weeks. All patients underwent a complete ophthalmological examination at baseline (T0) and at 1 (T1) and 2 (T2) weeks post-treatment. At each visit, the intraocular pressure (IOP) and the ocular surface disease index (OSDI) questionnaire scores were recorded; the Schirmer test was performed only at T0 and T2. The OSDI score significantly decreased in both the POAG and no-POAG groups (both p < 0.0001) after hydrocortisone treatment, with no difference between the two groups (p = 0.72). There were no significant differences in IOP and Schirmer test results between T0 and T2 in both treatment groups (p = 0.68 and p = 0.83, respectively). Topical low-dose (1,005 mg) preservative-free hydrocortisone is safe and effective for improving OSD symptoms both in patients with and without POAG. The trial was registered at clinicaltrials.gov under NCT04536129 on 01/09/2020 ("retrospectively registered").
Identifiants
pubmed: 34406502
doi: 10.1007/s00417-021-05345-3
pii: 10.1007/s00417-021-05345-3
doi:
Substances chimiques
Antihypertensive Agents
0
Ophthalmic Solutions
0
Preservatives, Pharmaceutical
0
Hydrocortisone
WI4X0X7BPJ
Banques de données
ClinicalTrials.gov
['NCT04536129']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-253Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Khanna RC (2017) Ocular surface disorders. Community Eye Health J 30(99):S1–S2
pubmed: 29849435
pmcid: 5968417
Akpek EK, Amescua G, Farid M, Garcia-Ferrer FJ, Lin A, Rhee MK et al (2019) American Academy of Ophthalmology Preferred Practice Pattern Cornea and External Disease Panel. Dry Eye Syndrome Preferred Practice Pattern®. Ophthalmology 126(1):P286–P334. https://doi.org/10.1016/j.ophtha.2018.10.023
doi: 10.1016/j.ophtha.2018.10.023
pubmed: 30366798
Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK et al (2017) TFOS DEWS II Report Executive Summary. Ocul Surf 15(4):802–812. https://doi.org/10.1016/j.jtos.2017.08.003
doi: 10.1016/j.jtos.2017.08.003
pubmed: 28797892
No Authors (2007) The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop .Ocul Surf 5(2):93–107. https://doi.org/10.1016/s1542-0124(12)70082-4
Lanza M, GironiCarnevale UA, Mele L, BifaniSconocchia M, Bartollino S, Costagliola C (2019) Morphological and functional evaluation of oral citicoline therapy in chronic open-angle glaucoma patients: a pilot study with a 2-year follow-up. Front Pharmacol 10:1117. https://doi.org/10.3389/fphar.2019.01117
doi: 10.3389/fphar.2019.01117
pubmed: 31611797
pmcid: 6775502
Costagliola C, dell’Omo R, Agnifili L, Bartollino S, Fea AM, Uva MG, Zeppa L, Mastropasqua L (2020) How many aqueous humor outflow pathways are there? Surv Ophthalmol 65(2):144–170. https://doi.org/10.1016/j.survophthal.2019.10.002
doi: 10.1016/j.survophthal.2019.10.002
pubmed: 31622628
European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th edition - chapter 2: classification and terminology Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 2 Classification and Terminology. (2017) Br J Ophthalmol 101(5):73–127. https://doi.org/10.1136/bjophthalmol-2016-EGSguideline.002
Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F (2010) Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 29(4):312–334. https://doi.org/10.1016/j.preteyeres.2010.03.001
doi: 10.1016/j.preteyeres.2010.03.001
pubmed: 20302969
Staso SDI, Agnifili L, Ciancaglini M, Murano G, Borrelli E, Mastropasqua L (2018) In vivo scanning laser confocal microscopy of conjunctival goblet cells in medically-controlled glaucoma. In Vivo 32(2):437–443. https://doi.org/10.21873/invivo.11259
doi: 10.21873/invivo.11259
Mohammed I, Kulkarni B, Faraj LA, Abbas A, Dua HS, King AJ (2020) Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: a 2-year randomized evaluation study. Clin Exp Ophthalmol 48(7):973–982. https://doi.org/10.1111/ceo.13814
doi: 10.1111/ceo.13814
pubmed: 32564453
Rossi GCM (2014) Diagnosis and treatment methods for ocular surface disease in glaucoma. European Ophthalmic Review 8(1):40–3. https://doi.org/10.17925/EOR.2014.08.01.40
doi: 10.17925/EOR.2014.08.01.40
Bucolo C, Fidilio A, Fresta CG, Lazzara F, Platania CBM, Cantarella G et al (2019) Ocular pharmacological profile of hydrocortisone in dry eye disease. Front Pharmacol 10:1240. https://doi.org/10.3389/fphar.2019.01240
doi: 10.3389/fphar.2019.01240
pubmed: 31680988
pmcid: 6813655
Feroze KB, Khazaeni L (2021) Steroid Induced Glaucoma. 2021 Jul 17. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL)
Kallab M, Szegedi S, Hommer N, Stegmann H, Kaya S, Werkmeister RM, Schmidl D, Schmetterer L, Garhöfer G (2020) Topical low dose preservative-free hydrocortisone reduces signs and symptoms in patients with chronic dry eye: a randomized clinical trial. Adv Ther 37(1):329–341. https://doi.org/10.1007/s12325-019-01137-8 (Erratum.In:AdvTher.2019Dec10)
doi: 10.1007/s12325-019-01137-8
pubmed: 31741283
Southren AL, Altman K, Vittek J, Boniuk V, Gordon GG (1976) Steroid metabolism in ocular tissues of the rabbit. Invest Ophthalmol 15(3):222–228
pubmed: 1254411
Doane MG, Jensen AD, Dohlman CH (1978) Penetration routes of topically applied eye medications. A J Ophthalmol 85:383–386
doi: 10.1016/S0002-9394(14)77735-9
Jin X, Qin Q, Tu L, Qu J (2009) Glucocorticoids inhibit the innate immune system of human corneal fibroblast through their suppression of toll-like receptors. Mol Vis 15:2435–41
pubmed: 19956406
pmcid: 2786883
Gao T, Lin Z, Jin X (2009) Hydrocortisone suppression of the expression of VEGF may relate to toll-like receptor (TLR) 2 and 4. Curr Eye Res 34(9):777–784. https://doi.org/10.1080/02713680903067919
doi: 10.1080/02713680903067919
pubmed: 19839871
Allocco AR, Ponce JA, Riera MJ, Magurno MG (2017) Critical pathway for primary open angle glaucoma diagnosis. Int J Ophthalmol 10(6):968–972. https://doi.org/10.18240/ijo.2017.06.21
doi: 10.18240/ijo.2017.06.21
pubmed: 28730090
pmcid: 5515164
Mathews PM, Ramulu PY, Friedman DS, Utine CA, Akpek EK (2013) Evaluation of ocular surface disease in patients with glaucoma. Ophthalmology 120(11):2241–2248. https://doi.org/10.1016/j.ophtha.2013.03.045
doi: 10.1016/j.ophtha.2013.03.045
pubmed: 23714318
Steven AJ (2010) Sample sizes for clinical trials. CRC Press, Taylor & Francis Group. A Chapman & Hall Book
Glymour MM, Weuve J, Berkman LF, Kawachi I, Robins JM (2005) When is baseline adjustment useful in analyses of change? An example with education and cognitive change. Am J Epidemiol 162(3):267–278
doi: 10.1093/aje/kwi187
Barnes PJ (2006) Corticosteroid effects on cell signalling. Eur Respir J 27(2):413–426. https://doi.org/10.1183/09031936.06.00125404
doi: 10.1183/09031936.06.00125404
pubmed: 16452600
Gupte R, Muse GW, Chinenov Y, Adelman K, Rogatsky I (2013) Glucocorticoid receptor represses proinflammatory genes at distinct steps of the transcription cycle. Proc Natl Acad Sci U S A 110(36):14616–14621. https://doi.org/10.1073/pnas.1309898110
doi: 10.1073/pnas.1309898110
pubmed: 23950223
pmcid: 3767553
Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N Engl J Med 353(16):1711–1723. https://doi.org/10.1056/NEJMra050541
doi: 10.1056/NEJMra050541
pubmed: 16236742
Sheppard JD, Comstock TL, Cavet ME (2016) Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther 33(4):532–52. https://doi.org/10.1007/s12325-016-0315-8
doi: 10.1007/s12325-016-0315-8
pubmed: 26984315
pmcid: 4846687
Kersey JP, Broadway DC (2006) Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond) 20(4):407–416. https://doi.org/10.1038/sj.eye.6701895
doi: 10.1038/sj.eye.6701895
Razeghinejad MR, Katz LJ (2012) Steroid-induced iatrogenic glaucoma. Ophthalmic Res 47(2):66–80. https://doi.org/10.1159/000328630
doi: 10.1159/000328630
pubmed: 21757964
Razeghinejad MR, Myers JS, Katz LJ (2011) Iatrogenic glaucoma secondary to medications. Am J Med 124(1):20–25. https://doi.org/10.1016/j.amjmed.2010.08.011
doi: 10.1016/j.amjmed.2010.08.011
pubmed: 21092926
Costagliola C, dell’Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F (2009) Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics. Expert Opin Pharmacother 10(16):2663–2677. https://doi.org/10.1517/14656560903300103
doi: 10.1517/14656560903300103
pubmed: 19874249
Armaly MF (1963) Effect of corticosteroids on intraocular pressure and fluid dynamics. i. the effect of dexamethasone in the normal eye. Arch Ophthalmol 70:482–491. https://doi.org/10.1001/archopht.1963.00960050484010
doi: 10.1001/archopht.1963.00960050484010
pubmed: 14078870
Becker B, Mills DW (1963) Corticosteroids and intraocular pressure. Arch Ophthalmol 70:500–507. https://doi.org/10.1001/archopht.1963.00960050502012
doi: 10.1001/archopht.1963.00960050502012
pubmed: 14078872
Jones R 3rd, Rhee DJ (2006) Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 17(2):163–167. https://doi.org/10.1097/01.icu.0000193079.55240.18
doi: 10.1097/01.icu.0000193079.55240.18
pubmed: 16552251